Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)

Page 1 of 2

Editor’s Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Acorda Therapeutics Inc (NASDAQ:ACOR), Myriad Genetics, Inc. (NASDAQ:MYGN)

Theravance Rises on FDA Staff Report on Lung Drug With Glaxo (Bloomberg)
Theravance Inc (NASDAQ:THRX) rose the most in a year after a staff report by U.S. regulators showed the once- daily lung disease treatment the company is developing with GlaxoSmithKline Plc (GSK) may be able to win approval. Theravance rose 20 percent to $28.62 at 10:15 a.m. New York time after reaching $29.11 for its biggest intraday gain since April 2012. The medication called Breo is meant to treat chronic obstructive pulmonary disease, an umbrella term for emphysema and chronic bronchitis.

VIVUS, Inc. (NASDAQ:VVUS) to make changes in its Risk Evaluation strategy (US Market Buzz)
VIVUS, Inc. (NASDAQ:VVUS)’s intention to revise the risk management plan for its anti-obesity drug Qsymia would not guarantee its success, a top shareholder of the company said. Qsymia, one of the two weight loss drugs approved by the US Food and Drug Administration, has not seen selling as successfully as expected.

Theravance Inc (NASDAQ:THRX)Amgen Stock Rating Reaffirmed by Barclays Capital (AMGN) (Daily Political)
Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “equal weight” rating reiterated by equities research analysts at Barclays Capital in a research note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $105.00 price target on the stock. A number of other analysts have also recently weighed in on AMGN. Analysts at UBS AG raised their price target on shares of Amgen from $98.00 to $121.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Lazard Capital Markets raised their price target on shares of Amgen, Inc. (NASDAQ:AMGN) from $106.00 to $125.00 in a research note to investors on Thursday.

Acorda Therapeutics rises on Ampyra study (San Francisco Chronicle)
Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) jumped Monday after the company said that its drug Ampyra helped stroke patients recover their ability to walk in a mid-stage clinical trial. Acorda said patients who took Ampyra recovered were able to walk faster and had an easier time performing daily tasks. The trial involved 83 patients who had an ischemic stroke at least six months earlier, and who still had walking problems. Ischemic strokes occur when a blood vessel that supplies blood to the brain is blocked.

Myriad Genetics CEO Claims He Owns Your Genes (Forbes)
Today, in a letter filled with non sequiturs and distortions, Myriad Genetics, Inc. (NASDAQ:MYGN)’s CEO Peter Meldrum, worried about whether his company will be able to maintain their monopoly on a test for which they charge $4000, responded. Let’s look at his claims. First, though, let me remind readers that the genes in question, BRCA1 and BRCA2, are linked to an increased risk of breast and ovarian cancer, a risk that was first discovered in 1994 by scientists at the University of Utah.

Theravance Inc (THRX): Here’s One Thing To Know About The Stock Today (Insider Monkey)
Theravance Inc (NASDAQ:THRX) has experienced a decrease in support from the world’s most elite money managers of late, but insiders on the whole appear bullish. More importantly, shares of Theravance are up more than…

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!